Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Li, Yan Li ^a   Gu, Kang Sheng ^a   Pan, Yue Yin ^a   Jiao, Yang ^a   Zhai, Zhi Min ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Absolute lymphocyte count absolute monocyte count ratio; Diffuse large B cell lymphoma; Relapse; SaaIPI; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ABSOLUTE LYMPHOCYTE COUNT ABSOLUTE MONOCYTE COUNT RATIO; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; BLOOD; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MONOCYTE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MONOCYTES; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STEM CELL TRANSPLANTATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901501239     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-341     Document Type: Article

References (49)

1. Habermann TM. New developments in the management of diffuse large B-cell lymphoma. Hematology 2012, (17):S93-S97.
2. Friedberg JW. Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Hematology Am Soc Hematol Educ Program 2011, 2011:498-505. 10.1182/asheducation-2011.1.498, 22160081.
3. Applebaum FR. Hematologic cell transplantation for non-Hodgkin lymphoma: yesterday, today, and tomorrow. J Clin Oncol 2008, 26:2927-2929. 10.1200/JCO.2007.15.7479, 18565876.
4. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184-4190. 10.1200/JCO.2010.28.1618, 3664033, 20660832.
5. Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, Song HS, Chung JS, Hyun MS, Sohn SK. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007, 21:2227-2230. 10.1038/sj.leu.2404780, 17554383.
6. Cox MC, Nofroni I, Laverde G, Ferrari A, Amodeo R, Tatarelli C, Saltarelli F, Veggia B, Aloe-Spiriti MA, Ruco L, Monarca B. Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 2008, 141:265-268. 10.1111/j.1365-2141.2008.07028.x, 18353165.
7. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients'survival benefit from rituximab. Eur J Haematol 2008, 81:448-453. 10.1111/j.1600-0609.2008.01129.x, 18691256.
8. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011, 25:1502-1509. 10.1038/leu.2011.112, 21606957.
9. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, JE R-U, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk 2013, 13:15-18. 10.1016/j.clml.2012.09.009, 23137719.
10. Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A, Barbui AM, Caracciolo D, Ladetto M, Gueli A, De Crescenzo A, Passera R, Devizzi L, Patti C, Gianni AM, Tarella C. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. Am J Hematol 2013, 88:1062-1067. 10.1002/ajh.23566, 23940056.
11. Li YL, Pan YY, Jiao Y, Ning J, Fan YG, Zhai ZM. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens. Ann Hematol 2014, 93:617-626. 10.1007/s00277-013-1916-9, 24141331.
12. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma 2012, 53:575-580. 10.3109/10428194.2011.637211, 22098403.
13. Watanabe R, Tomita N, Kishimoto K, Koyama S, Ogusa E, Ishii Y, Miyashita K, Matsuura S, Fujisawa S, Hattori Y, Takasaki H, Fujita A, Ohshima R, Kuwabara H, Hashimoto C, Fujimaki K, Sakai R, Ishigatsubo Y. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Res 2013, 37:1208-1212. 10.1016/j.leukres.2013.07.015, 23927994.
14. Bari A1, Tadmor T, Sacchi S, Marcheselli L, Liardo EV, Pozzi S, Luminari S, Baldini L, Marmiroli S, Federico M, Polliack A. Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. Leuk Res 2013, 37:619-623. 10.1016/j.leukres.2013.01.009, 23395384.
15. Huang JJ, Li YJ, Xia Y, Wang Y, Wei WX, Zhu YJ, Lin TY, Huang HQ, Jiang WQ, Li ZM. Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma. BMC Cancer 2013, 13:222. 10.1186/1471-2407-13-222, 3653743, 23638998.
16. Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, Go H, Kim JE, Kim CW, Huh J. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. Oncologist 2012, 17:871-880. 10.1634/theoncologist.2012-0034, 3380887, 22588324.
17. Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica 2012, 97:262-269. 10.3324/haematol.2011.050138, 3269488, 21993683.
18. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
19. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, et al. Stromal gene signatures in large-B- cell lymphomas. N Engl J Med 2008, 359:2313-2323. 10.1056/NEJMoa0802885, 19038878.
20. Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008, 93:1829-1836. 10.3324/haematol.13440, 18945747.
21. Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol 2009, 84:93-97. 10.1002/ajh.21337, 19123458.
22. Vellenga E, Putten WL VT, van Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, Huijgens PC. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial. Blood 2008, 111:537-543. 10.1182/blood-2007-08-108415, 17971487.
23. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Grouped'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126. 10.1200/JCO.2005.09.131, 15867204.
24. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010, 47:115-123. 10.1053/j.seminhematol.2010.01.011, 2848172, 20350658.
25. Dehghani M, Sharifpour S, Amirghofran Z, Zare HR. Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin's lymphoma patients. Med Oncol 2012, 29:2364-2371. 10.1007/s12032-012-0176-1, 22307765.
26. Gergely L, Váncsa A, Miltényi Z, Simon Z, Baráth S, Illés T. PretreatmentT lymphocytenumbers are contributing to the prognostic significance of absolute lymphocyte numbers in B-cell non-Hodgkins lymphomas. Pathol Oncol Res 2011, 17:249-255. 10.1007/s12253-010-9306-2, 20842470.
27. Głowala-Kosińska M, Chwieduk A, Nieckula J, Saduś-Wojciechowska M, Grosicki S, Rusin A, Nowara E, Giebel S. Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B cell lymphoma. Eur J Haematol 2013, 91:122-128. 10.1111/ejh.12144, 23679234.
28. Shafer D, Smith MR, Borghaei H, Millenson MM, Li T, Litwin S, Anad R, Al-Saleem T. Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. Leuk Res 2013, 37:1213-1215. 10.1016/j.leukres.2013.07.038, 23968916.
29. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of highnumbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008, 93:193-200. 10.3324/haematol.11702, 18223287.
30. Kim WY, Jeon YK, Kim TM, Kim JE, Kim YA, Lee SH, Kim DW, Heo DS, Kim CW. Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol 2009, 20:1688-1696. 10.1093/annonc/mdp056, 19542249.
31. Kim KH, Kim TM, Go H, Kim WY, Jeon YK, Lee SH, Kim DW, Khwarg SI, Kim CW, Heo DS. Clinical significance of tumor-infiltrating FOXP3+ T cells in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. Cancer Sci 2011, 102:1972-1976. 10.1111/j.1349-7006.2011.02051.x, 21812857.
32. Felcht M, Heck M, Weiss C, Becker JC, Dippel E, Müller CS, Nashan D, Sachse MM, Nicolay JP, Booken N, Goerdt S, Klemke CD. Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells. Br J Dermatol 2012, 167:348-358. 10.1111/j.1365-2133.2012.10987.x, 22512270.
33. Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, Shanyinde M, Lister TA, Calaminici M. Gribben JG: Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 2013, 31:256-262. 10.1200/JCO.2011.39.9881, 23045593.
34. Hasselblom S, Sigurdadottir M, Hansson U, Nilsson-Ehle H, Ridell B, Andersson PO. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol 2007, 137:364-373. 10.1111/j.1365-2141.2007.06593.x, 17456059.
35. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 3:162-174.
36. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, von der Maase H. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005, 93:273-278. 10.1038/sj.bjc.6602702, 2361564, 16052222.
37. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006, 24:1997-2005. 10.1200/JCO.2005.03.9594, 16648500.
38. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Chansky K, Kelly K, Adjei AA, Jett JR. A prognostic model for advanced stage nonsmall cell lung cancer: pooled analysis of North Central Cancer Treatment Group trials. Cancer 2006, 107:781-792. 10.1002/cncr.22049, 16847887.
39. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB. Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116:e74-e80. 10.1182/blood-2010-02-258558, 20628149.
40. Subimerb C, Pinlaor S, Lulitanond V, Khuntikeo N, Okada S, McGrath MS, Wongkham S. Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin Exp Immunol 2010, 16:471-479.
41. Schauer D, Starlinger P, Reiter C, Jahn N, Zajc P, Buchberger E, Bachleitner-Hofmann T, Bergmann M, Stift A, Gruenberger T, Brostjan C. Intermediate monocytes but not TIE2-expressing monocytes are a sensitive diagnostic indicator for colorectal cancer. PLoS One 2012, 7:e44450. 10.1371/journal.pone.0044450, 3433422, 22973451.
42. Feng AL, Zhu JK, Sun JT, Yang MX, Neckenig MR, Wang XW, Shao QQ, Song BF, Yang QF, Kong BH, Qu X. CD16+ monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis. Clin Exp Immunol 2011, 164:57-65. 10.1111/j.1365-2249.2011.04321.x, 3074217, 21361908.
43. Randolph GJ. No need to coax monocytes. Science 2011, 332:1268-1269. 10.1126/science.1208480, 21659591.
44. Hasselblom S, Hansson U, Sigurdardottir M, Nilsson-Ehle H, Ridell B, Andersson PO. Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 2008, 58:529-532. 10.1111/j.1440-1827.2008.02268.x, 18705775.
45. Wada N, Zaki MA, Hori Y, Hashimoto K, Tsukaguchi M, Tatsumi Y, Ishikawa J, Tominaga N, Sakoda H, Take H, Tsudo M, Kuwayama M, Morii E, Aozasa K. Tumor-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 2012, 60:313-319. 10.1111/j.1365-2559.2011.04096.x, 22211289.
46. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225. 10.1038/nature10138, 3208506, 21654748.
47. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, Fein M, Rasch MG, Tan YX, Qiu J, Park J, Sinha P, Bissell MJ, Frengen E, Werb Z, Egeblad M. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503. 10.1016/j.ccr.2012.02.017, 3332002, 22516258.
48. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD, Wang-Gillam A, Eberlein TJ, Denardo DG, Goedegebuure SP, Linehan DC. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res 2013, 19:3404-3415. 10.1158/1078-0432.CCR-13-0525, 23653148.
49. Olivieri A, Santini G, Patti C, Chisesi T, De Souza C, Rubagotti A, Aversa S, Billio A, Porcellini A, Candela M, Centurioni R, Congiu AM, Brunori M, Nati S, Spriano M, Vimercati R, Marino G, Contu A, Tedeschi L, Majolino I, Crugnola M, Sertoli MR. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Ann Oncol 2005, 16:1941-1948. 10.1093/annonc/mdi399, 16157621.